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The overall cure rate of colon cancer has not improved dramatically in the last decade, remaining at approximately 
60% S-year survival. The main reason for this lack of progress is that at the moment the primary tumour is 
resected, a significant proportion of the patients with seemingly localised disease already has (undetectable) 
micrometastases, mostly in the liver. The most important prognostic indicators have been extension of the tumour 
into the bowel wall and the presence of lymph node metastasis, as expressed in the Dukes classification. However, 
in the Dukes B and C categories, these parameters are poor predictors of final outcome. For improvement of the 
prognosis, in addition to earlier detection, more aggressive (adjuvant) treatment of high risk patients would be a 
rational strategy. This requires development of new therapeutic modalities, but also reliable stratification of 
patients according to high risk or low risk for recurrent disease. In recent years, many attempts have been made 
to improve the prediction of final outcome. Parameters studied include inflammatory response to the primary 
tumour, tumour cell growth fraction, turnout cell differentiation, genetic abnormalities and expression of genes 
involved in invasion and metastasis. Although some of these newer parameters have significant predictive value, 
in multivariant analyses, most appear to have limited independent value. Recent studies indicate that genetic 
abnormalities might be important new prognostic indicators. One of the most promising findings in this area is an 
allelic loss of chromosome 18q, which allows division of Dukes B patients into subgroups with low risk and high 
risk for recurrent disease. 
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INTRODUCTION 
IN THE clinical management of colorectal cancer, the pathologist 
plays a distinct role. During the diagnostic evaluation of a 
putative colorectal carcinoma patient, it is the pathologist who 
makes the final diagnosis, usually on an endoscopic biopsy 
specimen. This diagnosis will be confirmed through examination 
of the resection specimen. Of more importance than diagnostic 
confirmation is the determination of the extent of spread in the 
bowel wall and in regional lymph nodes. This information 
is indispensible for staging purposes. Staging is still mostly 
performed according to the Dukes classification, although the 
use of a TNM based staging system is becoming more popular. 
Tumour stage is the most important prognostic parameter. The 
predictive value of tumour stage, especially in the Dukes B and 
C categories (which correspond to stages II and III), is rather 
limited. Therefore, pathologists have explored a variety of 
possibilities to develop more detailed classification parameters, 
which would allow reliable prediction of tumour behaviour in the 
individual patient. Thus, in numerous studies, the prognostic 
significance of cancer cell differentiation, proliferative activity, 
expression of invasion and metastasis-related genes and genetic 
changes, including oncogene and tumour suppressor gene abnor- 
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malities, have been investigated. It is the purpose of this 
brief review to critically examine the significance of these new 
parameters for the clinical management of colorectal cancer. 
CONVENTIONAL STAGING 
It is generally recognised that tumour stage, as reflected for 
example in the Dukes classification, is one of the most powerful 
predictors of final outcome in colorectal cancer patients [ 11. The 
overall S-year survival rate of patients with colorectal cancer is 
approximately 60%. However, this differs greatly for the differ- 
ent stages (Table 1). For stage A (approximately 15% ofpatients) 
5-year survival exceeds 90% and, conversely, for Dukes D 
(approximately 10% of patients) this figure is between 5 and 
10%. For stage B, however, which constitutes approximately 
Table 1. Dukes stage and survival 
Stage 
S-year 
Proportion (%) survival (%) 
A 15 >90 
B 35 70 
C 50 30 
D 10 S-10 
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35% of patients, S-year survival is 70% and for Dukes C 
(about 50% of patients) this is approximately 30%. The lack of 
prognostic precision in stages B and C hampers stratification of 
patients into subgroups which might benefit from additional 
adjuvant therapy. Pathologists have responded to this problem 
by introducing new parameters which might have independent 
prognostic significance. More detailed histological evaluation of 
the pattern of invasion into the bowel wall or into veins has 
been advocated. Hase and associates [2] reported that irregular 
tumour cell budding at the invasive front of the tumour indicates 
more aggressive behaviour than a straight “pushing” tumour 
margin. Patients with a budding tumour margin showed 20% S- 
year survival against 70% in patients without budding. Budding 
frequency rose with Dukes stage, but, when stratified for stage 
budding remained an independent prognostic variable. Yamazoe 
and associates [3] investigated the depth of venous invasion as a 
predictor for liver metastasis. This parameter appeared to predict 
the occurrence of liver metastasis with high probability, 
especially in combination with desmoplastic reaction, lympho- 
cytic infiltration and depth of invasion. The extent of lympho- 
cytic infiltration was also taken into account in the classification 
proposed by Shepherd and associates [4]. The latter classification 
has gained some popularity, but has not become generally 
accepted. An important limitation of classifications based upon 
detailed histopathological criteria is their lack of reproducibility. 
Parameters, such as depth of venous invasion, budding and even 
intensity of lymphocytic infiltrate are often difficult to quantitate 
and, therefore, rather subjectively scored. 
An alternative approach towards more refined histopatholog- 
ical classification of tumour stage has been the detailed search 
for lymph node micrometastases by immunohistochemistry. 
Large clusters of cancer cells in a lymph node are easy to identify, 
but a few cancer cells in the marginal sinus might escape 
microscopical detection. Given the overall importance of lymph 
node involvement [5], a search for occult lymph node involve- 
ment might be a useful approach. Several studies have shown 
that, by using anti-cytokeratin antibodies, micrometastases can 
be detected in approximately 25% of cases that would otherwise 
have been classified as Dukes B [6, 71. What this means in terms 
of prognosis is less clear. Jeffers and colleagues [6] found no 
correlation between immunohistochemically identifiable 
micrometastases and age, sex, tumour size, tumour site or 
tumour differentiation, and no prognostic value for this para- 
meter. Greenson and associates [7] found higher survival in 
Dukes B patients without lymph node micrometastases, 
although the number of patients they studied was rather limited. 
This issue is, therefore, not yet resolved and deserves to be 
analysed further. 
TUMOUR DIFFERENTIATION 
By convention, in the histopathological evaluation of a colorec- 
tal carcinoma, the tumour is graded. In grading, cytonuclear 
features including nuclear pleomorphism, hyperchromasia and 
mitotic activity are taken into account. Furthermore, architec- 
tural features are assessed, which implies appraisal of the 
tendency of cancer cells to form differentiated structures, such 
as tubules, as well as cell polarity and mucin production. 
Conventional grading is performed in three categories: well, 
moderately well and poorly differentiated. Tumour grading has 
appeared to be somewhat subjective and not very reproducible. 
As a consequence, the prognostic relevance of tumour grade has 
tended to be rather limited [4]. Recent attempts to improve 
tumour grading have taken specific features of cancer cell 
differentiation into account. To this end, histochemical staining 
of specific cell types has been the most frequently used approach. 
Mucin production (indicative of goblet cell differentiation) can 
be demonstrated through conventional mucin stains. Columnar 
cells display immunoreactivity for secretory component and 
brush border-associated proteins, such as villin or sucrase- 
isomaltase. Endocrine cells are chromogranin A immunoreac- 
tive. Predominantly, the results of mucin staining and of staining 
for columnar cell-associated antigens has not yielded important 
new possibilities, although combinations of these antigens have 
been shown to convey some prognostically relevant information 
[8]. An interesting Iinding has been the detection of a subgroup 
of tumours with endocrine cells, as reflected in immunoreactivity 
for chromogranin A [9]. It has been shown that tumours with 
endocrine cells behave more aggressively than those without this 
characteristic, especially in the Dukes C category [9]. It is 
presently unclear what causes this difference. It has been 
proposed that carcinomas with endocrine cells consist of rela- 
tively primitive pluripotent cells which might be more aggress- 
ive. Alternatively, neurohormonal peptide production in a carci- 
noma might provide a paracrine growth stimulus. 
TUMOUR CELL PROLIFERATION 
In most malignant neoplasms, a correlation appears to exist 
between proliferative activity in the tumour and patient survival. 
Proliferative activity can be histologically assessed by counting 
mitoses, but because the M-phase is only a very short window in 
the total cell cycle, mitotic counts appear to be somewhat 
inaccurate. More recent approaches encompass the determi- 
nation of S-phase fraction by DNA-flow cytometry, metabolic 
labelling of DNA-synthesising cells using [3H]thymidine [lo] or 
bromodeoxyuridine and immunohistochemical staining of cell 
cycle related gene expression. Popular cell cycle-related antigens 
are proliferative cell nuclear antigen (PCNA, a DNA polymerase 
related protein [ 111) and the Ki67 antigen. The flow cytometric 
determination of S-phase fraction seems to be a relatively simple 
measure of proliferative activity. This technique, however, has 
two important limitations. Firstly, in carcinomas with multiple 
aneuploid stemlines in addition to diploid cells, it is not easy to 
determine the S-phase fraction on the basis of solid criteria. 
Secondly, most flow cytometric analyses are performed on 
material retrieved from paraffin sections [ 121. The precision of 
DNA measurement is limited in this type of material, and hence 
reliable S-phase fractions cannot be determined. In spite of these 
limitations, correlations between S-phase fraction and tumour 
behaviour have been found. Schutte and colleagues [ 131 reported 
a worse outcome in Dukes B patients with an S-phase fraction 
exceeding 15%. 
A much more popular approach towards proliferation analysis 
is immunohistochemical staining for PCNA or the Ki67 antigen. 
The latter is the favoured technique since, with the introduction 
of the MIB-1 antibody, this antigen can also be stained in 
paraffin sections (Figure 1). Mayer and associates [ 141 and Al- 
Shebener and associates [ 151 recently reported on the prognostic 
significance of PCNA expression. In both studies, a multivariant 
analysis was included. The data indicate that the percentage of 
PCNA positive cells is an independent predictor of tumour 
behaviour, the higher PCNA index indicating a shorter survival. 
Silvestrini and colleagues [lo] showed, by [3H]thymidine label- 
ling of metastatic colon cancer cells in the liver, that even when 
liver metastases are present cell proliferation may be a useful 
prognostic marker. Thus, proliferative activity as reflected in a 
PCNA index or (preferably) a Ki67 index (using the MIB-1 
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Figure 1. Immunohistochemical staining of the proliferation associ- 
ated antigen Ki67 (using the MIB-1 antibody) in a poorly differentiated 
carcinoma of the colon. Most cancer cell nuclei are positive, indica- 
tive of a high growth fraction (X 400). 
antibody) might be used as an additional parameter for clinical 
decision-making. 
TUMOUR INVASION AND METASTASES 
For tumour subclassification, much attention has been paid 
to parameters which are related to invasive and metastatic 
behaviour. This has been done using histological parameters 
such as tumour “budding” [2], venous invasion [3] and lymph 
node micrometastasis [5, 61. More recent possibilities include 
the detection of basement membrane deposits [16], the 
expression of proteases involved in tumour cell invasion [ 17, 181, 
the expression of metastasis-related genes such as the nm23 
gene [ 191, and the expression of cell adhesion molecules [20], 
including variant forms of CD44 [2 11. 
Havenith and associates [16] studied the prognostic signifi- 
cance of basement membrane staining in colorectal cancer. 
These investigators noted that, in the tumour periphery, cancer 
cells did not have a basement membrane, but in the tumour 
centre a variable amount of this material was deposited. Increas- 
ing basement membrane deposition correlated with better prog- 
nosis. These authors postulated that the host response to the 
tumour is reflected in the extent of deposition of extracellular 
matrix. 
The prognostic value of the expression of matrix proteases 
was recently studied by Mulcahy and colleagues [18] and by 
Ganesh and colleagues [ 171. Mulcahy’s group [ 181 stained col- 
orectal cancer tissues for the urokinase type plasminogen acti- 
vator (uPA). In Dukes B patients, high grade uPA staining 
indicated a high probability of the development of liver metast- 
ases. Ganesh and associates [ 171 measured levels of the different 
components of the plasminogen activator/plasmin system 
(including uPA, t(tissue type)PA, and the inhibitors PAI- and 
PAI-2) in normal and cancer tissue by immunoassay. These 
authors found the ratio of UPA in cancer tissue/tPA in normal 
mucosa and the PAI- level in cancer tissue to be independent 
prognostic variables. It seems, therefore, that determination of 
matrix proteases might be useful in the development of new 
subclassifications of colorectal cancer with prognostic value. 
In search of new markers for metastatic disease, the ~223 
gene has received wide attention (see MacDonald and associates, 
pp. 10961100). This gene was discovered through the gener- 
ation of a monoclonal antibody which differentially labelled 
metastatic and non-metastatic melanoma cells. Recently, loss of 
the nm23 gene has been reported to correlate with the occurrence 
of distant metastases in colorectal cancer [19]. For colorectal 
cancer, the nm23 findings have been somewhat conllicting, 
however, and consequently this finding needs to be further 
confirmed. 
Another area of promising development has been that of cell 
adhesion molecules. On the assumption that loss of intercellular 
adhesion would precede cancer cell invasion, the expression of 
the crucial epithelial cell adhesion molecule, E-cadherin, has 
been studied in colorectal cancer [20]. It has become clear 
that E-cadherin expression is highly correlated with tumour 
differentiation (Figure 2), and may not be an independent 
prognostic variable. Another limitation of E-cadherin as an 
invasion marker is that loss of expression of a few cells is 
much more difficult to detect (let alone to quantitate) than 
overexpression. This limitation is not shared by the CD44 family 
of adhesion molecules. CD44 is widely expressed on leucocytes 
and serves as a leucocyte adhesion molecule, with a regulating 
function in leucocyte traffic. Following cloning of the CD44 
gene, it was discovered that this gene can be alternatively spliced, 
which results in a family of related proteins derived from a 
single gene. Subsequent studies have shown that the variant 
(alternatively spliced) forms of the CD44 molecule are expressed 
in specific patterns on normal and neoplastic epithelial cells. The 
v6 variant was shown to be expressed on a subgroup of colorectal 
carcinomas (Figure 3), and it was established that v6 expression 
is strongly correlated with tumour progression [21]. Although 
prospective testing of the clinical use of CD44 v6 staining is still 
not complete, it is expected that this might become an important 
new prognostic marker in colorectal cancer. 
Figure 2. E-cadherin immunoreactivity in a moderately differen- 
tiated adenocarcinoma. Irregular cell strands show intense 
intercellular staining (X 400). 
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Figure 3. CD44 (~6) immunoreactivity in a moderately differentiated 
adenocarcinoma. Focally the hunour cells show intense intercellular 
staining (X 400). 
TUMOUR CELL GENETICS 
No solid tumour has been studied as intensely as colorectal 
cancer for molecular genetic abnormalities. The pioneering work 
of Vogelstein and collaborators led to the definition of a series of 
molecular genetic abnormalities which together determine the 
neoplastic phenotype of a colorectal cancer cell [22]. Although 
well accepted in cancer cell biology, the clinical use of this 
molecular genetic model of colorectal carcinogenesis remains to 
be established. 
Clinical testing of gross genetic abnormalities, as reflected in 
an abnormal DNA content of the cancer cells which can be 
determined by DNA flow cytometry, has been reported repeat- 
edly [23, 241. Ploidy analysis is relatively simple and fast, and 
could, therefore, be of practical use if it would provide a strong 
independent new predictor for prognosis. Most studies, to date, 
indicate that patients with aneuploid tumour cell populations, 
in general, have a shorter survival than patients with diploid 
tumours. Tumour ploidy, however, is signilicantly correlated 
with other prognostically relevant variables, including Dukes 
stage, tumour grade and proliferative activity, and, therefore, as 
an independent prognostic indicator, ploidy has appeared of 
limited value [23, 241. 
Although technically more complex, detailed molecular gen- 
etic analysis of colorectal cancer in search of prognostically 
relevant parameters could potentially yield highly valuable infor- 
mation which could be used in clinical management. Recent 
developments in this methodology have allowed the use of 
even paraffin-embedded archival material for molecular genetic 
analysis [25]. The oncogenes and tumour suppressor genes of 
interest for the study of colorectal cancer can be directly inferred 
from Vogelstein’s model of colorectal carcinogenesis [22]. KI- 
RAS oncogene mutations are assumed to function early in 
colorectal carcinogenesis. Consequently, KI-RAS mutations are 
found in a high percentage of colorectal cancers. It was even 
recently shown that in precancerous conditions as well as in 
inflammatory bowel disease without overt dysplasia ICI-RAS 
mutations may occur [26]. In spite of their putative early role in 
colorectal carcinogenesis, KT-JZAS mutations appeared to be 
independent predictors of unfavourable outcome in several 
studies [27, 281. 
Interesting observations on the pattern of mutations on codon 
12 of the KZ-RAS were recently reported by Moerkerk and 
associates [28]. These authors observed only G->A mutations in 
Dukes B, but predominantly G-X or G->T mutations in 
Dukes C turnours. This observation suggests that a Dukes C 
tumour is not merely a later stage of progression of a Dukes B 
tumour, but possibly a different tumour subgroup with a 
different pathway of molecular carcinogenesis. This possibility, 
however, needs to be confirmed. 
Bell and associates [27] investigated the predictive value of 
codon- KZ-RAS mutations for patient survival. This para- 
meter appeared not to have any prognostic significance as 
an independent variable. When taken together with TPS3 
overexpression, as detected by immunocytochemistry, KI-RAS 
mutations identified a subgroup of patients with shorter survival. 
Abnormalities in the TP53 gene have received ample attention 
in colorectal cancer research. In the Vogelstein model, TPS3 is 
postulated to function late in colorectal carcinogenesis. This is 
in agreement with the observation that with increasing dysplasia 
in adenomas the percentage of cases with TP53 abnormalities 
rises. Of all colorectal carcinomas, approximately 70% show 
TP53 abnormalities. In a PCR-based study, Hamelin and associ- 
ates [29] convincingly demonstrated a strong correlation between 
the presence of TP53 mutations and shorter survival. In muhiva- 
riate analysis, this parameter appeared to be independent from 
other prognostic variables. Mutations of TP53 can also be 
detected by immunocytochemistry because the mutated proteins 
appear to have a prolonged half-life, which leads to their 
accumulation in the nuclei of mutated cells (Figure 4). Yamagu- 
chi and colleagues [30] studied the prognostic significance of 
TP53 overexpression by immunocytochemistry. In primary 
tumours, TP53 expression was not correlated with any other 
histological variable. However, patients with a TP53 positive 
tumour showed a higher risk of developing liver metastases. 
Accordingly, in the Dukes C category, TP53 overexpression 
appeared to be a highly significant predictor of prognosis in 
terms of the 5-year survival rate. 
Figure 4. Immunostaining for ~53 in a well differentiated carcinoma 
(X 4W. 
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In a recent study, Jen and colleagues [25] reported on the 
significance of allelic loss of chromosome 18q in colorectal 
cancer. These authors investigated 18q status using polymorphic 
microsatellite markers in a PCR-based assay on paraffin- 
embedded tissue. Chromosome 18q was chosen in view of the 
fact that it is frequently deleted in colon cancer (hence the name 
of the associated oncogene: deleted in colon cancer or DCC). Of 
all turnours, 67% showed 18q allelic loss. With increasing stage, 
the frequency of allelic loss also increased. Tumours with allelic 
loss were often (70%) located in the right side of the colon. When 
stratified for stage, 18q allelic loss was strongly correlated with 
survival in stage II (which corresponds with Dukes B) patients. 
In fact, stage II patients could be divided according to 18q allelic 
loss into a subgroup which behaved as stage I (no loss) and a 
subgroup which behaved as stage III (loss). In view of the high 
probability of the existence of correlations between the different 
prognostic parameters, a multiple regression analysis was perfor- 
med. In all models, 18q allelic loss had a highly significant 
independent effect on prognosis. 
CONCLUSION 
In reviewing the available data concerning pathological 
characteristics of colorectal cancer (Table 2) it is clear that 
conventional anatomical (depth of invasion, lymph node involve- 
ment, liver metastases) and histological parameters (vascular 
and perineural invasion, lymphocyte infiltration and to a lesser 
extent tumour differentiation) continue to provide a solid basis 
for the purposes of prognosis. It is also clear, however, that 
improvement in the prognosis of colorectal carcinoma will have 
to come either from earlier detection and secondary prevention 
or from more effective therapy. For more effective therapy, 
adjuvant treatment modalities are available and more effective 
new modalities are being, or will be, developed. Reliable stratifi- 
cation of particularly Dukes B and C (or stages II and III) 
patients into subgroups with low and high risk of recurrent 
disease will be essential. This is where pathology will have its 
most significant impact on the clinical management of colorectal 
cancer. Prognostic factors, however, will only become clinically 
significant when they are used in clinical decision-making. 
The clinical use of prognostic factors should be assessed in 
Table 2. Pathological parameters with progtwstic significance 








Depth of invasion Strong 
Lymph node metastasis Strong 
Liver metastasis Strong 
Differentiation Weak 
S-phase fraction Weak 
Proliferation markers (PCNA, Ki67) Weak 
Basement membranes Weak 







18q loss Strong 
prospective studies. The most promising new prognostic factors 
have resulted from cancer cell genetics. With the advent of 
techniques to identify reliably, even in routinely processed tissue 
specimens, relevant molecular genetic characteristics of tumour 
cells, it may be expected that, in terms of predicting outcome in 
individual patients, enormous progress will be made in the 
coming years. As yet, the basis of tumour classification will 
remain classical histopathology, but molecular pathology will 
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